Season 12: episode 1
As 2026 gets underway, healthcare and life sciences face a year of both promise and pressure, with investment, innovation and equity all in sharp focus.
In Part 1 of this year’s pharma forecast, four leaders explore where real opportunity lies, from health investment to personalisation and women’s health, alongside the key threats that could slow progress. In Part 2, they discuss the biggest unknowns for the year ahead and share a personal goal they’re working towards in 2026.
Speaker bios
Vice President and Head of Global Scientific Communications, GSK
Dheepa leads strategy and execution across oncology, vaccines, specialty care and general medicine, driving innovation in how scientific narratives are delivered.
Senior Vice President of European Markets, BMS
Emma oversees Bristol Myers Squibb’s operations across 19 countries of Europe, bringing extensive global leadership experience spanning Europe, Asia, Latin America and the Middle East.
Omnichannel expert
Within the pharmaceutical sector, Yacin specialises in shaping seamless customer journeys, driving content activation and aligning global strategies with local execution.
CEO, Healthcare Businesswomen’s Association
Mary leads a global organisation that advances representative leadership, strengthens the talent pipeline for healthcare and life sciences, and fuels business growth across the sector.
